Anthem Biosciences: Strong Margins and Strategic Growth Amidst Market Headwinds

Anthem Biosciences Limited, a prominent player in the biotechnology sector, recently unveiled its financial results for the third quarter and nine months ended December 31, 2025 (Q3 & 9M FY26). While the company navigated a challenging market environment marked by destocking and a higher base from the previous year, its strategic initiatives and operational efficiencies shone through, particularly in margin expansion. The consolidated revenue from operations for Q3 FY26 stood at ₹423.2 crore, with a 15.0% year-on-year decline. However, the nine-month period demonstrated resilience, with revenue from operations growing by 11.2% year-on-year to ₹1,513.4 crore. Profit after Tax (PAT) for Q3 FY26 was ₹92.8 crore, reflecting a PAT margin of 20.3%, while 9M FY26 PAT reached ₹402.0 crore, with a robust PAT margin of 24.8%. The company's EBITDA margins saw a significant improvement, rising from 35.2% in Q3 FY25 to 41.8% in Q3 FY26, underscoring its focus on profitability and operational leverage.

The company's performance was largely driven by its two core segments: Contract Research, Development, and Manufacturing Organization (CRDMO) and Specialty Ingredients. In Q3 FY26, the CRDMO business contributed ₹333.2 crore, accounting for 78.8% of the operational revenue, while Specialty Ingredients brought in ₹89.9 crore, making up the remaining 21.2%. For the nine-month period, CRDMO revenue was ₹1,259.9 crore (83.2%), and Specialty Ingredients contributed ₹253.5 crore (16.8%). The management attributed the Q3 revenue dip to a higher base in the previous year and broader market uncertainties, including customer destocking. Despite this, the underlying demand remains robust, and the company is confident in a strong finish to the financial year, traditionally its strongest quarter.

Strategic Pillars for Future Growth

Anthem Biosciences is strategically positioning itself for sustained long-term growth through several key initiatives. A significant driver of the improved margins is the company's successful backward integration. It has completely discontinued sourcing intermediates from China, opting instead for in-house manufacturing. This move has not only enhanced material margins but also solidified its position as one of the most backward integrated companies in the country for specific products. This strategic shift provides greater control over the supply chain and reduces external dependencies.

Capacity expansion remains a cornerstone of its growth strategy. The company is undertaking a substantial capital expenditure of ₹1,000 crore over two years for its Unit-4 facility. This expansion is meticulously planned to support future demand, focusing on small-scale molecules, peptides, fermentation, and high-potent oncology products. Management emphasized the importance of building capacity in advance to attract new customers and facilitate the progression of pipeline projects from development to commercialization. The company's strong balance sheet, with a net cash position of ₹1,231.2 crore as of December 31, 2025, provides the necessary financial muscle for these ambitious projects.

Diversification and Innovation in Product Portfolio

Anthem Biosciences is also making significant strides in diversifying its product portfolio, particularly in high-growth areas like peptides and biosimilars. The company has made substantial investments in developing peptide chemistries and is actively engaged in 8-9 innovator peptide programs. Its strong capabilities in this area have attracted innovator companies seeking partnerships for new peptide development. Furthermore, Anthem Biosciences is well-positioned to capitalize on the generic GLP-1 (Semaglutide) market, leveraging its backward integration to offer competitive pricing. The management highlighted that peptide development is a long-term play, with GLP-1 representing a more immediate opportunity.

In the biosimilar space, the company is developing a microbial biosimilar product for an approved drug for a US customer. The strategy involves shifting the manufacturing of this biosimilar from outside India to Anthem's facilities, capitalizing on its technology and cost advantages. This initiative is expected to contribute significantly to future revenue, with market entry anticipated in the next two years for advanced projects. Additionally, Anthem Biosciences is investing in fermentation for probiotic work, aiming to supply probiotic strains for import substitution in the Indian market and expanding into Rest of World (ROW) markets, marking probiotics as a significant growth driver in the specialty ingredient segment.

Outlook and Management Confidence

Looking ahead, Anthem Biosciences' management expressed confidence in its growth trajectory. For the full year FY26, the company expects revenue growth in the mid-teens (15-16%) and anticipates EBITDA and PAT margins to remain upwards of 20%. The fourth quarter is traditionally the strongest, and management expects a robust performance to conclude the financial year. For FY27, the company projects growth closer to 20%, driven by the ramp-up of existing commercial products and new launches. The company also disclosed an exceptional item of ₹25.4 crore in 9M FY26 due to the new Labour Codes, which it is actively monitoring for finalization of rules. Despite the short-term market headwinds, Anthem Biosciences' strategic investments in capacity, backward integration, and a diversified product pipeline underscore its commitment to sustained growth and value creation for its stakeholders. The company's proactive approach to market trends and disciplined capital allocation positions it favorably for future success in the dynamic biotechnology landscape.